EMA Authorised: Vyloy (zolbetuximab) — Astellas Pharma Europe B.V.

View source ↗

Summary

EMA authorised Vyloy (zolbetuximab) for gastric and esophageal cancers; the medicine has orphan designation and is developed by Astellas Pharma Europe B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• VYLOY (ZOLBETUXIMAB)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Esophageal Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 22/01/2026. Orphan medicine